R&D channel feed

PTC finds it­self in quag­mire of reg­u­la­to­ry set­backs, push­es back time­line on PKU treat­ment

Last year
FDA+

Ot­su­ka’s AD­HD as­set suc­ceeds in reg­is­tra­tional tri­als with chil­dren and teens

Last year

Sanofi shakes up clin­i­cal plans for trio of pro­grams from De­nali, Prin­cip­ia and Kymab deals

Last year
Pharma

Prime Med­i­cine show­cas­es its first in vi­vo edit­ing da­ta in mon­keys and mice

Last year
Cell/Gene Tx

Sanofi will spin out con­sumer unit, putting weight be­hind R&D ef­forts: ‘I have to in­vest in the sci­ence now’

Last year
Pharma

Mer­ck’s Keytru­da sales eclipse $18B on the year, while num­bers for Lagevrio sur­prise

Last year
Pharma

Bris­tol My­ers push­es back ‘peak’ for new prod­uct sales, cit­ing chal­leng­ing up­take for So­tyk­tu, Camzyos

Last year
Pharma

Like Mod­er­na, pan­dem­ic peers Pfiz­er and BioN­Tech head to PhI­II with Covid/flu com­bo jab

Last year
Pharma
Coronavirus

In­ject­ed form of Leqem­bi ap­pears ef­fec­tive at clear­ing amy­loid, but with no­table risks

Last year
Pharma

When treat­ing Alzheimer’s, ear­li­er is bet­ter, ac­cord­ing to analy­sis of Lil­ly and Ei­sai tri­als

Last year

‘Ex­cit­ed to be back’: Roche’s se­quel to failed Alzheimer’s an­ti­body looks promis­ing in ear­ly study

Last year

BioX­cel says in­de­pen­dent au­dit of Alzheimer’s study found mis­con­duct did not im­pact da­ta re­li­a­bil­i­ty

Last year

Bio­gen touts glimpses of ef­fi­ca­cy in ear­ly study of tau-low­er­ing drug

Last year

Scoop: Mer­ck scraps PhII tri­als of Alzheimer’s and de­pres­sion small mol­e­cule af­ter liv­er tox­i­c­i­ty ob­ser­va­tions

Last year
Pharma

Gri­fol­s' Alzheimer’s vac­cine ap­pears safe, but ef­fi­ca­cy un­clear, in PhII study

Last year

Im­mutep touts mid-stage da­ta for LAG-3 drug in first-line NSCLC, fi­nal­iz­ing plans for PhI­II test: #ES­MO23

Last year

Up­dat­ed: No­var­tis 'on track' to com­plete re­struc­tur­ing post San­doz spin, push­es back Plu­vic­to fil­ing

Last year
Pharma

Heard at #ES­MO23: No­var­tis and BeiGene fall­out; Now I know my AD­Cs; and a stand­ing ova­tion

Last year

New Plu­vic­to da­ta point to a po­ten­tial wider in­di­ca­tion, but No­var­tis leaves reg­u­la­to­ry time­line up in the air: #ES­MO23

Last year

BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

Last year
Cell/Gene Tx
Manufacturing

How J&J’s Ry­bre­vant com­bo stacks up against As­traZeneca’s Tagris­so in EGFR-mu­tat­ed lung can­cer: #ES­MO23

Last year

Up­dat­ed: Verve plans first in-hu­man base edit­ing tri­al in the US af­ter FDA lifts clin­i­cal hold

Last year
Cell/Gene Tx

As­traZeneca, Dai­ichi Sankyo still need key over­all sur­vival re­sults on TROP2 ADC in breast, lung can­cer: #ES­MO23

Last year
Pharma

Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

Last year
First page Previous page 66676869707172 Next page Last page
A service from the Financial Times